UCB Stock price

Equities

UCB

BE0003739530

Pharmaceuticals

Market Closed - Euronext Bruxelles 11:37:28 2024-03-01 am EST 5-day change 1st Jan Change
108.6 EUR +1.92% Intraday chart for UCB +12.58% +37.58%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 5.62B 6.09B Sales 2025 * 6.23B 6.75B Capitalization 20.6B 22.32B
Net income 2024 * 446M 483M Net income 2025 * 953M 1.03B EV / Sales 2024 * 3.98 x
Net Debt 2024 * 1.8B 1.95B Net Debt 2025 * 688M 746M EV / Sales 2025 * 3.42 x
P/E ratio 2024 *
45.2 x
P/E ratio 2025 *
23.3 x
Employees 8,767
Yield 2024 *
1.3%
Yield 2025 *
1.51%
Free-Float 61.42%
More Fundamentals * Assessed data
Dynamic Chart
Global markets live: Reckitt, Apple, Warner, Eli Llily, Intel... Our Logo
UCB : H2 beat; the prospects remain encouraging Alphavalue
Transcript : UCB SA, 2023 Earnings Call, Feb 28, 2024
UCB SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ZILBRYSQ® Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis in Adult Patients Who Are Anti-Acetylcholine Receptor Antibody Positive CI
Drugmakers set to raise U.S. prices on at least 500 drugs in January RE
UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society Annual Meeting CI
Strides Pharma Science Arm Gets US FDA's Nod for Generic Seizure Treatment MT
UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis CI
UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor CI
UCB Presents New Five-Year Data on Bimzelx® (Bimekizumab-Bkzx) in Ankylosing Spondylitis CI
UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio CI
UCB SA Announces Publication of NAYZILAM® Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function for People with Seizure Clusters CI
Global markets live: United Airlines, General Motors, VMware, Nvidia, Exxon Mobil... Our Logo
UCB Gets US FDA Approval for Psoriasis Drug DJ
More news
1 day+1.92%
1 week+12.58%
Current month+1.92%
1 month+24.97%
3 months+51.86%
6 months+30.69%
Current year+37.58%
More quotes
1 week
95.60
Extreme 95.6
109.40
1 month
85.76
Extreme 85.76
109.40
Current year
78.72
Extreme 78.72
109.40
1 year
65.40
Extreme 65.4
109.40
3 years
65.40
Extreme 65.4
116.05
5 years
60.18
Extreme 60.18
116.05
10 years
54.53
Extreme 54.53
116.05
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 11-05-31
Director of Finance/CFO 57 20-06-30
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 65 16-04-27
Director/Board Member 73 13-12-31
Chief Executive Officer 65 11-05-31
More insiders
Date Price Change Volume
24-03-01 108.6 +1.92% 419,672
24-02-29 106.5 +1.43% 1,138,438
24-02-28 105 +8.09% 828,017
24-02-27 97.14 +0.52% 247,873
24-02-26 96.64 +0.23% 250,487

Real-time Euronext Bruxelles, March 01, 2024 at 11:37 am EST

More quotes
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
108.6 EUR
Average target price
105.2 EUR
Spread / Average Target
-3.07%
Consensus
  1. Stock
  2. Equities
  3. Stock UCB - Euronext Bruxelles
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW